Gilead Sciences Inc. (GILD)
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Gilead Sciences (GILD) Fell More Than Broader Market
Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.
WHO recommends Gilead's twice-yearly injection for HIV prevention
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.
